Automated and Rapid Microbiological Tests: Market Research Report

Date: October 1, 2011
Pages: 660
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A6B2F59672BEN
Leaflet:

Download PDF Leaflet

Automated and Rapid Microbiological Tests: Market Research Report
This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Million by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications.

The report provides separate comprehensive analytics for the US, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

A six-year historic analysis is also provided for these markets.

The report profiles 93 companies including many key and niche players such as Abbott Laboratories, Abbott Diagnostics, Alere Inc., Becton Dickinson and Company, bioMerieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Sekisui Diagnostics, Siemens Healthcare Diagnostics, Inc., Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Clinical Applications
Automated Identification and Susceptibility Systems
Automated Blood Culture Systems
Automated Tuberculosis Systems
Streptococcal Infection Rapid Tests
GC/Chlamydia Rapid Tests
Other Automated & Rapid Microbiological Tests
Non-Clinical Applications

2. INDUSTRY OVERVIEW

Outlook
Evolutionary Battle Against Bugs Drives Market Future
Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market
Traditional Rapid Microbiological Tests Destined to Go Out With the Old
A Current & Future Analysis
Segmental Perspective
Clinical Applications
Non-Clinical Applications
Macro: The Big Picture
Deciding the Market’s Future
A Holistic Peek into a Few Noteworthy Trends
Biotechnology & Rapid Microbial Tests
Automated & Rapid Microbiological Tests: “Current Market Stance”
A Business Case for Automated & Rapid Microbiological Testing
Near Patient Testing: An Offshoot of Rapid Microbiological Tests
Pros & Cons of Near Patient Testing
Role of Near Patient Testing in Reducing Antibiotic Resistance in Humans
The Pre/Post Microbial Rapid Testing Era: A Review
Market Structure
Competitive Setup of the Diverse Automated & Rapid Microbiology Products Market
Competitive Landscape

Table 1. World Market for Microorganism Identification and Resistance Tests by Leading Players (2010): Market Share Breakdown of Value Share for BioMerieux; Becton, Dickinson and Co; and Others (includes corresponding Graph/Chart)
Table 2. World In-Vitro Diagnostics (IVD) Market by Leading Players (2010): Market Share Breakdown for Roche, Siemens, Abbott Diagnostics, Becton Dickinson, Beckman Coulter and Others (includes corresponding Graph/Chart)
Table 3. World Blood Screening Market by Leading Players (2010): Market Share Breakdown for Gen-Probe/Novartis, Roche, and Others (includes corresponding Graph/Chart)

3. MARKET TRENDS & ISSUES

Advancements in Molecular Diagnostics - A Boon or a Threat
Leading Companies in Molecular Diagnostics Market
Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing
Instant Detection of Pathogens – A New Epoch in the Fight for Survival
Lower Cost Rapid Tests Built on Multiple Sampling Modalities – Gaining Momentum
“Time Constraints?” - Rapid Tests to the Rescue
Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease
Accuracy/Reliability of Home HIV Testing: A Bone of Contention
Development of Near Patient Test Kits: A Market Driven Phenomenon
Near Patient Test Kits: A Rumination of Possibilities
Automated Blood Culture Systems: A Winning Edge in the Fight Against Bacteremia
Leading Food Processors Resort to Rapid Microbiological Testing
Impact of Food Scares on Rapid Microbiological Tests Market
Demand for Microbiological Tests & Level of QC in the Food Industry
Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market
Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests
Key Advantages/Benefits of Rapid Microbiological Tests on Food
Food Packages of the Future Ingrained with Microbial Alert Systems
Technology Innovations in Rapid Food Microbial Testing: A Historic Brief
Obtaining Regulatory Approval – A Major Non-Technical Hindrance

4. FACTORS INFLUENCING THE MARKET

Continuing Biological Warfare with Pathogens Sparks Market Growth
Innovative Products – A Key Growth Strategy
Other Market Drivers in a Capsule
Low Turnaround Times Skyrocket Demand
Greater Patient Awareness
Rising Incidence of STDs Kindles Universal Market Acceptance
Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV-Epidemic
Validation of Rapid Microbiological Tests: An Imperative Prerequisite
Non-Conformance to Testing Requirements: A Weighty Concern
Influenza – Boosting Rapid Test Prospects

5. PRODUCT/TECHNOLOGY OVERVIEW

Automated & Rapid Microbiological Tests: A Definition
Benefits of Automated & Rapid Microbiological Tests
Classification of Rapid Microbiological Test Methods
How Does a Rapid Test Work?
Sample Preparation – A Key Procedure
Automated Identification and Susceptibility Systems
Automated Blood Culture Systems
Automated Tuberculosis Systems
Microminiaturization of Diagnostic Tests: How Is It Effected?
Advantages of Microminiaturisation:
Acid-Fast Microscopy – The Forerunner of Rapid Tests
Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood
Enabling Technologies of Automated & Rapid Microbiological Tests
Growth-based Technologies
Viability-based Technologies
Cellular-Component or Artifact-based Technologies
Genomics/ Proteomics
Microarrays/Microfluidics
DNA Microchips/Probes
Polymerase Chain Reaction (PCR)
Immunoassay
Immunoassay Escalates into Diverse Fields of Diagnostic Testing
Nucleic Acid Testing (NAT)
Nucleic Acid Probes
Signal-Amplified Tests
Nucleic Acid Amplification Tests
Traditional Methods with Computer-Aided Imaging
Combination Methods

6. END-USE APPLICATION ANALYSIS

Applications in Clinical Investigations
STD Rapid Tests
GC/Chlamydia Rapid Tests
HIV Rapid Tests
HIV Facts & Figures

Table 4. Global Prevalence of HIV Infection by Region: 2007 & 2008 (includes corresponding Graph/Chart)
Table 5. Global HIV Related Deaths by Region: 2007 & 2008 (includes corresponding Graph/Chart)
Table 6. Global Distribution of HIV Prevalence, Incidence and Mortality: 2008 (includes corresponding Graph/Chart)

Advantages of Rapid HIV Testing
Disadvantages of Rapid HIV Testing
Syphilis Rapid Tests
Respiratory Rapid Tests
RSV/ Influenza Rapid Tests
Tuberculosis Rapid Tests
Group A beta Hemolytic Streptococcus Rapid Tests
Mononucleosis Rapid Tests
Streptococcus Rapid Tests
Streptococcus A Rapid Tests
Streptococcus B Rapid Tests
Gastrointestinal Rapid Tests
Giardia Lamblia Rapid Tests
H. Pylori Rapid Tests
Cryptosporidium Rapid Tests
C. Difficile Rapid Tests
Applications in Non-Clinical Investigations
Food/Water Safety Tests
Food Safety Testing: A Lucrative Application Area
Rapid Microbiological Methods in Pharmaceutical Sector
Limitations of RMMs
Advantages of RMMs
Applications in Pharmaceutical Sector
Environmental Tests
Other Miscellaneous Applications

7. PRODUCT INNOVATIONS/INTRODUCTIONS

BioControl Systems Develops PCR for Detecting Non-O157 Serotypes of STEC
InDevR Introduces New Virus Counter
MicroPhage Receives Approval from FDA for KeyPath™ MRSA/MSSA Blood Culture Test – BT
Health Canada Approves DuPont’s BAX® System Real-Time Assay
Neogen Receives Approval from AOAC for Reveal 2. 0 Test
Life Technologies and University of Pennsylvania School of Veterinary Medicine Introduce TaqMan® Salmonella enteritidis Detection Kit
AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic Light™ PNA FISH®
Pall Introduces GeneDisc Rapid Microbiology System
Abbott Laboratories Introduces PLEX-ID™ Biothreat Assay
bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA
BD Launches BD Max™ Open System
Luxcel Biosciences and Mocon Develop GreenLight™900 Series
Bruker Launches pTD™ for Homeland Security
Hygiena International Launches EnSURE
Researchers at University of Georgia Develop Pneumonia Diagnostic Test
BD Diagnostics Obtains Approval from FDA for BD MAX™ GBS Assay
bioMerieux Receives Approval for TEMPO® STA from AOAC and AFNOR
Bruker Introduces MALDI Sepsityper™ Kit
AdvanDx Introduces GNR Traffic Light™ PNA FISH®
ZyGEM Launches Microbial Fingerprinting Diagnostic Technology
BD Diagnostics Launches BD BACTEC™ MGIT™ 320 Mycobacteria Culture System
Particle Measuring Systems Launches BioLaz™ Real-Time Microbial Monitor
NanoLogix Launches Quick-Test Product Line
MOCON Introduces GreenLight™ Screening System
Life Technologies Unveils MicroSEQ® Rapid Microbial Identification System
IDEXX Laboratories Launch Enterolert®-DW in Europe
Alere Rolls Out three Cardiac Testing Solutions
Millipore Introduces New Milliflex Quantum Rapid Microbiological Test Method
BD Diagnostics Adds Automated Microbiology Specimen Processor to its Diagnostic Portfolio
Roche Introduces New Automatic Clinical Laboratory System, Cobas®4800
Thermo Fisher Scientific Launches an Automated Photometric Method
Thermo Fisher Scientific Introduces Salmonella Rapid Culture Method
BD Receives FDA Clearance for BD ProbeTec Amplified DNA Assays on BD Viper System
Oxoid Introduces Xpect® Flu A&B
Oxoid Extends ProSpecT Range
Oxoid Launches ELISA Systems Test Kits Range
Oxoid Introduces Brilliance VRE Agar and Brilliance ESBL Agar
Oxoid Launches RapID Kits
Inverness Medical Innovations Introduces C. DIFF QUIK CHEK COMPLETETM Rapid Test
Celsis International Launches Celsis ReACTTM
Roche Diagnostics Introduces LightCycler® Mycobacterium Detection Kit
bioMerieux Introduces NucliSENS EasyQ® HIV-1 v2. 0
Celsis International Unveils RapiScreenTM Beverage
Siemens Launches MicroScan Synergies plus® gram-positive ID/MIC and MIC Combination Panels
Oxoid Introduces IDEIATM Norovirus
Oxoid Introduces Salmonella PrecisTM Process
Remel Offers FDA Approved RPMI 1640 Agar w/MOPS and 2% Glucose
Oxoid Launches Rapid MDG Broth
Lonza Introduces microCompass TYMC (Total Yeast and Mould Count) Detection Kit
Inverness Medical Introduces Determine HIV-1/2 Ag/Ab Combo
Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr Virus
Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species

8. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST – A PERSPECTIVE BUILDER

Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus Diagnostic Microbiology Systems
Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelect™ test, in US
bioMerieux Introduces VIDAS®, an automated Clostridium difficile A & B Toxins Detection Test
Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E. coli O157 and Salmonella
Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440 Molecular System
Oxoid Unveils Remel Xpect™ Clostridium Difficile Toxin A/B Test
Neogen Introduces Soleris System
ATCC Introduces Authenticult™ Quality Control Microbiological Testing Tool
Bio-Rad Introduces New EBV Kits
Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test
Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test
FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood
FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection
bioMerieux Introduces TEMPO® Quality Indicator Testing System
Biotrace Introduces Tecra Unique Campylobacter Rapid Test
bioMerieux Introduces TEMPO® EB test for Enterobacteriaceae
Roche Unveils Elecsys TORCH Assays
Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan
bioMerieux Develops Advanced Colorimetry™ NH Card
Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU
Oxoid Launches New Rapid Test for Salmonella Detection in Food Products
Oxoid Unveils New Contact Plate Design
FDA Approves Fluconazole Susceptibility Tests from BioMerieux
Polysciences Unveils New Microbiological & Bacterial Detection Applications
Researchers Develop New Rapid MODS Test for TB Detection
Dade Behring Unveils Automated Quadriga BeFree System
FDA Approves Abbott PRISM® HBsAg Assay
Bayer’s EHIV Test Receives FDA Clearance
Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens
Roche Diagnostics’ cobas TaqScreen MPX Test Receives CE Mark Approval
Cepheid Introduces Rapid Xpert® MRSA Test in Europe
Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella
Chemogen Develops New Tuberculosis Rapid Test
bioMerieux Rolls Out VIDAS® LDUO Test
Zonda Develops New Rapid Test for Chlamydia
MedMira Launches MiraCare Rapid HIV Test
STMicroelectronics and Mobidiag Unveil Lab-On-Chip
Vermicon Launches ScanVIT-Legionella Rapid Test Kit
New Line of Rapid Microbial Detection Systems from Centrus
OraSure Rolls Out OraQuick ADVANCE
Abbott Unveils Automated HCV Test
ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory Pathogens
Biophage Pharma Offers Service for Microbiological Testing
bioMerieux Releases New Rapid Test for Nosocomial Infections
bioMerieux Widens Product Portfolio with Addition of TEMPO® System

9. RECENT INDUSTRY ACTIVITY

Sekisui Chemical Acquires Diagnostic Products Business of Genzyme
Dynacare Laboratories Acquires Bruker MALDI Biotyper System
Magellan Biosciences Enters into Partnership with miacom Diagnostics
Lonza Signs Distribution Agreement with Roche
BD Enters into Collaboration with Bruker Daltonics
Seegene Enters into Partnership with Molzym
bioMerieux Enters into Partnership with Shanghai Institutes for Biological Sciences
Becton, Dickinson and Company Acquires Global Rights to Market Micro PRO
Rapid Micro Biosystems Enters Into Partnership with Life Technologies
DuPont and U. S. Department of Agriculture to Collaborate for New Microbiological Test
bioMerieux and Biocartis Enter into Partnership
BD Diagnostics Collaborates with Lonza Group
Rapid Micro Biosystems Signs Contract with BARDA
Shimadzu and bioMerieux Enter into Partnership
Micro Identification Technologies and OSI Optoelectronics Sign Agreement
Inverness Medical Adopts New Corporate Identity
Thermo Fisher Acquires Ahura Scientific
Don Whitley Signs Distribution Agreement with Zisys
Charm Sciences Acquires MLX Microplate Luminometer Product Line from Dynex Technologies
Alpha Analytical Acquires Boston Analytical Inc.
Roche Group Acquires Genentech
Roche Acquires Innovatis AG
3M TAKES OVER BIOTRACE INTERNATIONAL
Lab21 Buys Majority Stake in Biotec Laboratories
Vacci-Test Acquires Maxivet
bioMerieux Acquires PML Microbiologicals
3M ACQUIRES FOOD DIAGNOSTICS AS
Becton, Dickinson and Company Receives License for its GeneOhmTM from Health Canada
BD Diagnostics Receives CE Marking for BD GeneOhmTM VanR Test
bioMerieux Bags AOAC Research Institute's Performance- Tested Methods SM Approval
MedMira Receives Sales Approval of Multiplo HBV/HIV/HCV Rapid Tests Market
Schering-Plough Inks International Collaboration Agreement with OraSure Technologies
Roche Selects Quidel's Influenza Test
Quidel Enters into Global Alliance with bioMerieux
Premier's QUEST Selects Remel SpectraTM MRSA
Thermo Fisher Scientific and MedAssets Supply Chain Systems Enter into a Supply Agreement
Thermo Fisher Scientific Bags FDA Approval for SpectraTM MRSA
Advantest to Take Over Credence Systems
DSM Food Specialties to Acquire CMT Srl
Sysmex Signs Agreement with bioMerieux
Nanogen Enters into Definitive Agreement with Elitech Group
Silliker Acquires Majority Stake in EGI Laboratory
BD Establishes New Rapid Diagnostic Products Manufacturing Facility in China
Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue(R) RSV Test
Siemens Obtains US FDA Approval for its VERSANT™ 440 Molecular System
bioMerieux to Market Wescor’s Customized Slide Stainer Instruments under bioMerieux Brand
Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV Test
Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV-II Blood Screening Test
Quidel and bioMerieux Form a Long-term Alliance in Rapid Diagnostic Tests
BD Diagnostics Obtains US FDA Approval for BD GeneOhm™ StaphSR Assay

10. CORPORATE ACTIVITY IN RECENT PAST – A PERSPECTIVE BUILDER

Siemens Acquires Dade Behring
Concateno Acquires Euromed
Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests
Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business Division in Lenexa
OraSure and SCMS Enter into an Agreement for Supplying OraQuick(R) HIV Test to PEPFAR Countries
Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test
Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System for Testing Donated Blood
AdvanDx Ropes In bioMerieux for Distributing its Rapid Diagnostic Tests in US

3M AND GEN-PROBE JOIN HANDS TO DEVELOP RAPID MOLECULAR TESTS FOR DETECTING HAIS

Gen-Probe’s PROCLEIX® TIGRIS® System Obtains US FDA Approval for Screening Donated Blood for West Nile Virus
3M ACQUIRES ACOLYTE BIOMEDICA
Formation of Siemens Medical Solutions Diagnostics
bioMerieux Bags Contract to Provide VITEK® 2 System for Scottish NHS Labs
bioMerieux Licenses NorChip’s HPV Test Technology for Cervical Cancer
bioMerieux in Strategic Agreement with Cepheid for Sepsis Assays
3M HEALTH CARE CREATES NEW MEDICAL DIAGNOSTICS UNIT
Schering-Plough & OraSure to Develop Rapid Oral HCV Test
3M ACQUIRES BIOTRACE INTERNATIONAL
Siemens Acquires DPC
Oxoid Acquires Microbiology Business Activities of Dako
Inverness Acquires IDT and Thermo BioStar
BMD in Agreement with MND for Research on Diagnostic Tests
Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test
Dutch Government Grants €7. 9 Million to FIND
FIND and Hain to Develop Rapid Test for MDR and XDR TB
3M & GEN-PROBE ALLY FOR DEVELOPING RAPID MOLECULAR TESTS FOR FOOD SAFETY
Bio View Inks Three-Year Distribution Agreement with Abbott Molecular
Bodycote Acquires Foodscan Laboratories
Cepheid Bags STTR Funding for Development of Rapid TB Test
Abbott and Verax in Distribution Agreement for Verax Platelet PGD® Test
BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers
Abbott & ARC in Agreement for Automated Blood Screening Tests
BD to Set Up Production Facility for Rapid Diagnostic Products in China
BD Diagnostics Delivers STI Testing Products to BioReference
Meridian Licenses LAMP Diagnostic Test Technology from Eiken
OraSure Inks Multi-Year Purchase Contract with New York City
Abbott Inks Single-Source Agreement with Novation for HIV Test
Neogen Takes Over Centrus International
Becton, Dickinson and Company Acquires GeneOhm Sciences
Inverness Medical Innovations Makes a Synergetic Purchase of ACON Laboratories
Quest Diagnostics Strikes Deal with BD Diagnostics
Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test
TREK Diagnostic and Novation Inks Agreement
Clinton Foundation Inks Agreement with Four Companies to Cut Prices
Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2 Rapid Test PMAs
Roche’s LightCycler SeptiFast Test Attains CE Mark
Zonda Expands Distribution of Products in Europe
OraSure Wins Rapid HIV Tests Order
MedMira Secures Orders for Rapid HIV Tests
Cepheid Collaborates with Foundation for Innovative Diagnostics
Chembio Obtains Clearance for Rapid HIV Tests in Kenya
Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay
MedMira Obtains CE Mark for MiraCare
Setema to Distribute Chembio’s Rapid HIV Tests in Ethiopia
Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid HIV Tests
Quidel Acquires immunochemical Fecal Occult Blood Test
Xact Aid Snaps Up STD Alert
Grant Life Sciences Acquires Rapid Tests from AccuDx
Millipore Ties Up with Gen-Probe
Foundation for Innovative New Diagnostics forms Collaboration with Eiken Chemical
WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement
Akers Biosciences Enters into a Distribution Agreement with Alco Industries
Celsis and BioVentures Enter into Licensing Agreement
Thermo Electron Inks Pact with Genomic Profiling Systems
Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid HIV-1/2 Test
bioMerieux Signs Agreement with Novel Diagnostics
Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels
OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics
BD Diagnostics Receives FDA Approval for BD Directigen™ EZ Flu A+B Test
BD Diagnostics Bags FDA Clearance for BBL™ CHROMagar™ MRSA Product
MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China
Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus Assay
Medical Services International Secures Clearance for Rapid Test Kits
Medical Services International Receives Exclusive Marketing Rights for TB Test Kit
Adaltis Receives Orders for HIV Rapid Tests from China
MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test
Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform
Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing
Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test

11. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
Abbott Diagnostics (USA)
Alere Inc. (US)
Becton Dickinson and Company (USA)
bioMerieux SA (France)
bioMerieux, Inc. (USA)
Bio-Rad Laboratories, Inc (USA)
Cellabs Pty Ltd (Australia)
Celsis International Plc (UK)
Coris BioConcept (Belgium)
F. Hoffmann-La Roche Ltd. (Switzerland)
Gen-Probe Inc. (USA)
MedMira, Inc. (Canada)
Meridian Biosciences, Inc. (USA)
Orasure Technologies, Inc. (USA)
Orion Diagnostica Oy (Finland)
Quidel Corp. (USA)
Sekisui Diagnostics (Japan)
Siemens Healthcare Diagnostics, Inc. (USA)
Thermo Fisher Scientific, Inc. (USA)
Remel, Inc. (USA)
Oxoid Limited (UK)

12. GLOBAL MARKET PERSPECTIVE

Table 7. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 8. World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 9. World 15-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 10. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 11. World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 12. World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 13. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 14. World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 15. World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used – Percentage Breakdown of Revenues for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 16. World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 17. World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 18. World 15-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 19. World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 20. World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 21. World 15-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 22. World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 23. World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 24. World 15-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 25. World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 26. World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 27. World 15-Year Perspective for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 28. World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 29. World Historic Review for GC/Chlamydia Rapid Tests (*) in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 30. World 15-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 31. World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 32. World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 33. World 15-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 34. World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 35. World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 36. World 15-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region – Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

13. THE UNITED STATES

A. Market Analysis
A Current & Future Analysis
Rapid Microbiology Tests - A Competitive Profile
Consolidation in the Automated and Rapid Microbiological Tests Market
Bioterrorism Tests – Gaining Prominence
Tracking Trends Across Product Segments
STD Rapid Tests
Market Share Trends of Leading Players

Table 37. Leading Players in the US Market for GC/Chlamydia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe, Abbott, Becton Dickinson and Roche (includes corresponding Graph/Chart)
Table 38. Leading Players in the US Market for Chlamydia Rapid Tests (2010) – Percentage Breakdown of Value Sales by Company for Thermo Fischer Scientific, Alere ,and Quidel (includes corresponding Graph/Chart)
Table 39. Leading Players in the US Market for Syphilis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Alere, and Others (includes corresponding Graph/Chart)

Leading Players in HIV Rapid Testing Market
Gastrointestinal Rapid Tests
Market Share Data of Leading Players

Table 40. Leading Players in the US Market for C. Difficile Rapid Tests (2010) –Percentage Breakdown of Value Sales by Company for Alere, Meridian Biosciences, BioSite, Becton Dickinson, Thermo Fischer Scientific, and Others (includes corresponding Graph/Chart)
Table 41. Leading Players in the US Market for Cryptosporidium Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes correspondingGraph/Chart)
Table 42. Leading Players in the US Market for Rotavirus Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart)
Table 43. Leading Players in the US Market for Giardia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes corresponding Graph/Chart)

Respiratory Rapid Tests
Competition
Market Share Data of Leading Players

Table 44. Leading Players in the US Market for Influenza Rapid Tests (2010) – Percentage Breakdown of Value Sales by Company for Quidel, Becton Dickinson, Thermo Fischer Scientific and Others (includes corresponding Graph/Chart)
Table 45. Leading Players in the US Market for RSV Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Binax,,Thermo Fischer Scientific and Others (includes corresponding Graph/Chart)
Table 46. Leading Players in the US Market for Tuberculosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe and Becton Dickinson (includes corresponding Graph/Chart)
Table 47. Leading Players in the US Market for M. Pneumoniae Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, and Remel, Inc. (includes corresponding Graph/Chart)
Table 48. Leading Players in the US Market for Mononucleosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Alere, Remel, Quidel, and Others (includes corresponding Graph/Chart)

Streptococcus Infection Rapid Tests
Market Share Data of Leading Players

Table 49. Leading Players in the US Market for Streptococcus A Rapid Tests (2010) -Percentage Breakdown of Value Sales by Company for Quidel, Thermo Fischer Scientific, Becton Dickinson, and Others (includes corresponding Graph/Chart)

A Peek into the Testing Practices of the US Food Industry
B. Market Analytics

Table 50. US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 51. US Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 52. US 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 53. US Recent Past, Current & Future Analysis for Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 54. US Historic Review for Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 55. US 15-Year Perspective for Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14. EUROPE

A. Market Analysis
A Current & Future Analysis
European Market Primer
What Drives the Requirement Patterns of End-Users?
Competitive Profile
Trends & Issues
Proliferation of Automated, and Rapid Tests in Europe
European Automated Market
Probe Tests: “A Crack in the Future of Rapid Tests”
Trends Across Product Segments
GC/Chlamydia Rapid Tests
Streptococcal Infection (Strep A) Rapid Tests
Automated Tuberculosis Systems Market
B. Market Analytics

Table 56. European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region – France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 57. European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region – France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 58. European 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region – Percentage Breakdown of Revenues for France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 59. European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 60. European Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 61. European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14A. FRANCE

A. Market Analysis
A Current & Future Analysis
bioMerieux: A Key Player
B. Market Analytics

Table 62. French Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 includes corresponding Graph/Chart)
Table 63. French Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 64. French 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14B. GERMANY

A. Market Analysis
A Current & Future Analysis
Competitive Structure
B. Market Analytics

Table 65. German Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 66. German Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 67. German 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14C. ITALY

A. Market Analysis
A Current & Future Analysis
B. Market Analytics

Table 68. Italian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 69. Italian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 70. Italian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14D. THE UNITED KINGDOM

A. Market Analysis
A Current & Future Analysis
Increasing Incidence of MRSA Spur Growth in Rapid Diagnostics
B. Market Analytics

Table 71. UK Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 72. UK Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 73. UK 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14E. SPAIN

A. Market Analysis
A Current & Future Analysis
B. Market Analytics

Table 74. Spanish Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 75. Spanish Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 76. Spanish 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14F. RUSSIA

A. Market Analysis
A Current & Future Analysis
B. Market Analytics

Table 77. Russian Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 78. Russian Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 79. Russian 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14G. REST OF EUROPE

A. Market Analysis
A Current & Future Analysis
B. Market Analytics

Table 80. Rest of Europe Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 81. Rest of Europe Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 82. Rest of Europe 15-Year Perspective for Automated & Rapid Microbiological Tests by Product Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15. REST OF WORLD

A. Market Analysis
A Current & Future Analysis
Latin America
Asia-Pacific – The Next Epicenter for the AIDS Epidemic
Demand for Advanced Microbiology Instruments and Testing Methods Set to Grow in India
B. Market Analytics

Table 83. Rest of World Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 84. Rest of World Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment – Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 85. Rest of World 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment – Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Total Companies Profiled: 93 (including Divisions/Subsidiaries - 109)
Region/CountryPlayers
The United States67
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Future German Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 983 pages
Future Italian Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 970 pages
Future Japanese Microbiology Testing Market Outlook US$ 6,240.00 Feb, 2012 · 976 pages
Future Spanish Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 960 pages
Future UK Microbiology Testing Market Outlook US$ 4,720.00 Feb, 2012 · 978 pages

Ask Your Question

Automated and Rapid Microbiological Tests: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: